{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:48:05Z","timestamp":1794718085229,"version":"4.9.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar","award":["G03\/181 and FIS PI12\/01289"],"award-info":[{"award-number":["G03\/181 and FIS PI12\/01289"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["08-2008"],"award-info":[{"award-number":["08-2008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centro Nacional de Investigaci\u00f3n Cardiovascular"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\u2003<\/jats:title>\n                  <jats:p>Knowledge of the features of patients with familial hypercholesterolaemia (FH) who are protected from atherosclerotic cardiovascular disease (ASCVD) is important for the clinical and prognostic care of this apparently high-risk condition. Our aim was to investigate the determinant and characteristics of patients with FH who are protected from ASCVD and have normal life expectancy, so-called \u2018resilient\u2019 FH (R-FH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results\u2003<\/jats:title>\n                  <jats:p>Spanish Familial Hypercholesterolaemia cohort study (SAFEHEART) is an open, multicentre, nation-wide, long-term prospective cohort study in genetically defined patients with heterozygous FH in Spain. Patients in the registry who at the time of analysis were at least 65\u2009years or those who would have reached that age had they not died from an ASCVD event were analysed as a case\u2013control study. Resilient FH was defined as the presence of a pathogenic mutation causative of FH in a patient aged \u226565\u2009years without clinical ASCVD. Nine hundred and thirty registrants with FH met the study criteria. A defective low-density lipoprotein (LDL)-receptor mutation, higher plasma level of high-density lipoprotein cholesterol (HDL-C), younger age, female gender, absence of hypertension, and lower plasma lipoprotein (a) [Lp(a)] concentration were independently predictive of R-FH. In a second model, higher levels of HDL-C and lower 10-year score in SAFEHEART-RE were also independently predictive of R-FH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion\u2003<\/jats:title>\n                  <jats:p>Resilient FH may be typified as being female and having a defective LDL-receptor mutation, higher levels of plasma HDL-C, lower levels of Lp(a), and an absence of hypertension. The implications of this type of FH for clinical practice guidelines and the value for service design and optional care of FH remains to be established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov number NCT02693548.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwab185","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T11:01:33Z","timestamp":1634727693000},"page":"795-801","source":"Crossref","is-referenced-by-count":27,"title":["A resilient type of familial hypercholesterolaemia: case\u2013control follow-up of genetically characterized older patients in the SAFEHEART cohort"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9706-7783","authenticated-orcid":false,"given":"Leopoldo","family":"P\u00e9rez de Isla","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico San Carlos, IDISSC, Facultad de Medicina, Universidad Complutense, C\/Profesor Mart\u00edn Lagos s\/n, 28040 Madrid, Spain"},{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar, C\/General Alvarez de Castro 14, 28010 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Cardiology, Royal Perth Hospital, Lipid Disorders Clinic, Cardiometabolic Services, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-6556","authenticated-orcid":false,"given":"Ovidio","family":"Mu\u00f1iz-Grijalvo","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"D\u00edaz-D\u00edaz","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Abente y Lago, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-1245","authenticated-orcid":false,"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar, C\/General Alvarez de Castro 14, 28010 Madrid, Spain"},{"name":"Center for Advanced Metabolic Medicine and Nutrition, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zamb\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-7366","authenticated-orcid":false,"given":"Francisco","family":"Fuentes-Jimenez","sequence":"additional","affiliation":[{"name":"Lipid and Atherosclerosis Unit, CIBERObn, IMBIC, Hospital Universitario Reina Sofia, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-5829","authenticated-orcid":false,"given":"Marta","family":"Mauri","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital de Terrassa, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-954X","authenticated-orcid":false,"given":"Teresa","family":"Padr\u00f3","sequence":"additional","affiliation":[{"name":"ICCC Cardiovascular, Institut de Recerca del Hospital Santa Creu i Sant Pau, IIB Santa Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 I","family":"Vidal-Pardo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Barba","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Complejo Hospitalario Universitario, Albacete, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ruiz-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-6224","authenticated-orcid":false,"given":"Alfredo","family":"Mich\u00e1n","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Jerez de la Frontera, Cadiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D","family":"Mediavilla","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-3583","authenticated-orcid":false,"given":"Antonio M","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2794-9710","authenticated-orcid":false,"given":"Manuel J","family":"Romero-Jimenez","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Infanta Elena, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Lucus Augusti, Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mata","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar, C\/General Alvarez de Castro 14, 28010 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SAFEHEART Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"2022050522132746600_zwab185-B1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2022050522132746600_zwab185-B2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2022050522132746600_zwab185-B3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MOL.0000000000000553","article-title":"Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?","volume":"29","author":"Mata","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"2022050522132746600_zwab185-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022050522132746600_zwab185-B5","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022050522132746600_zwab185-B6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"P\u00e9rez De Isla","year":"2017","journal-title":"Circulation"},{"key":"2022050522132746600_zwab185-B7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1476-511X-10-94","article-title":"Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)","volume":"10","author":"Mata","year":"2011","journal-title":"Lipids Health Dis"},{"key":"2022050522132746600_zwab185-B8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.12.012","article-title":"Familial hypercholesterolemia and cardiovascular disease in older individuals","volume":"318","author":"Coutinho","year":"2021","journal-title":"Atherosclerosis"},{"key":"2022050522132746600_zwab185-B9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCGEN.120.002938","article-title":"Familial hypercholesterolemia in a healthy elderly population","volume":"13","author":"Lacaze","year":"2020","journal-title":"Circ Genomic Precis Med"},{"key":"2022050522132746600_zwab185-B10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2022050522132746600_zwab185-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2021.04.011","article-title":"Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: a clinical practice experience","author":"Alonso","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2022050522132746600_zwab185-B12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2022050522132746600_zwab185-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOL.0000000000000519","article-title":"Predicting cardiovascular disease in familial hypercholesterolemia","volume":"29","author":"Paquette","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"2022050522132746600_zwab185-B14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/ATVBAHA.118.312414","article-title":"Liquid biopsy of extracellular microvesicles maps coronary calcification and atherosclerotic plaque in asymptomatic patients with familial hypercholesterolemia: a computed tomographic angiography imaging study","volume":"39","author":"Chiva-Blanch","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022050522132746600_zwab185-B15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamacardio.2020.0819","article-title":"Sex differences in ischemic heart disease\u2014the paradox persists","volume":"5","author":"Mendirichaga","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022050522132746600_zwab185-B16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamacardio.2020.0822","article-title":"Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: secondary analysis of the ISCHEMIA randomized clinical trial","volume":"5","author":"Reynolds","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022050522132746600_zwab185-B17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/jcm10010064","article-title":"Identifying markers of cardiovascular event-free survival in familial hypercholesterolemia","volume":"10","author":"Khoury","year":"2020","journal-title":"J Clin Med"},{"key":"2022050522132746600_zwab185-B18","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022050522132746600_zwab185-B19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022050522132746600_zwab185-B20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/cge.13648","article-title":"A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment","volume":"97","author":"Ellis","year":"2020","journal-title":"Clin Genet"},{"key":"2022050522132746600_zwab185-B21","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/s41467-020-17374-3","article-title":"Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions","volume":"11","author":"Fahed","year":"2020","journal-title":"Nat Commun Nat Res"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/5\/795\/43567005\/zwab185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/5\/795\/43567005\/zwab185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T22:16:18Z","timestamp":1651788978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/5\/795\/6448263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,2]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwab185","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,12,2]]}}}